期刊文献+

厄贝沙坦对高胆固醇血症大鼠肾PAI-1活性的影响 被引量:1

Effect of Irbesartan on PAI-1 Activity in Renal Cortex in Hypercholesterolemia Rats
下载PDF
导出
摘要 目的 :①了解纤溶酶原激活物抑制剂 1(PAI 1)在高胆固醇大鼠血及肾皮质的表达及其与肾脏损害的关系 ;②探讨厄贝沙坦对高胆固醇血症PAI 1活性的影响。方法 :Wistar大鼠随机分为 3组 :正常组、高脂组和厄贝沙坦组 ,12周后测定血浆及肾皮质PAI 1活性。石蜡切片行HE、PAS染色观察一般病理变化 ,免疫组化检测纤连蛋白和Ⅳ型胶原的表达。结果 :与对照组相比 ,高脂组血浆及肾皮质PAI 1活性明显升高 ,系膜基质增多 ,系膜区纤连蛋白和Ⅳ型胶原增多 ,厄贝沙坦组肾皮质PAI 1活性和纤连蛋白、Ⅳ型胶原较高脂组低 ,但仍较正常组高 ,PAI 1活性与纤连蛋白和Ⅳ型胶原呈显著正相关。结论 :高胆固醇血症大鼠肾皮质PAI 1活性增加 ,可能与肾小球细胞外基质积聚有一定关系 ,可能参与脂质肾损害的进展 ,厄贝沙坦可部分阻止这种作用。 Objective: To investigate the protein expression of plasminogen activator inhibitor(PAI 1) in renal tissue of hypercholesterolemia rats and the effect of Irbesartan. Methods: Forty Wistar rats were divided into three groups in random, one group were fed on hyperlipid diet (H group),one group were fed on hyperlipid diet and Irbersartan (HT group),the other group were fed on normal diet(C group). The renal pathological changes were observed, the activity of PAI 1 in serum and renal cortex were determined after 12 weeks and the protein expression of collagen Ⅳ and fibronectin were examined by immunochemistry. Results: Compared with control group,PAI 1 activity in serum and renal cortex and the expression of collagen Ⅳ and fibronectin increased significantly in H group. PAI 1 activity have a positive relationship with collagen Ⅳ and fibronectin. Conclusion: Increased PAI 1 activity in serum and renal cortex may be related to glomerular matrix accumulation and may stimulate the progress of lipoid nephrosis. Irbersatan can partly prevent this effect.
出处 《武汉大学学报(医学版)》 CAS 2003年第4期329-331,共3页 Medical Journal of Wuhan University
关键词 厄贝沙坦 高胆固醇血症 大鼠 肾PAI-1活性 影响 hypercholesterolemia plasminogen activator inhibitor 1 angiotensin Ⅱ receptor
  • 相关文献

参考文献6

  • 1何永成,廖履坦,丁小强,张月娥,徐元钊,徐元鼎.高胆固醇血症对健康大鼠肾脏形态学的影响[J].肾脏病与透析肾移植杂志,2000,9(1):34-38. 被引量:8
  • 2王建中,陈香美,师锁柱,张燕平.Ⅰ型纤溶酶原激活物抑制物在IgA肾病肾小管间质损伤中的作用研究[J].中华肾脏病杂志,2000,16(1):11-15. 被引量:32
  • 3Rerolle JP, Hertig A, Nguyen G, et al. Plasminogen activator inhibitor type 1 is a potential target in renal fibrogenesis. Kidney Int,2000,58:1 841.
  • 4Oikawa T, Freeman M, Lo W, et al. Modulation of plasminogen activator inhibitor-1 in vivo :A new mechanism for the anti-fibrotic effect of rennin-angiotensin inhibition. Kidney Int, 1997,51:164.
  • 5Ma LJ, Nakamura S, Whitsett J, et al. Regression of glomerulosclerosis in aging by angiotensin Ⅱ type 1 receptor antagonist(AIIRA) is linked to inhibition of plasminogen activator inhibitor-1(PAI-1). J Am Soc Nephrol, 1999,10:576A.
  • 6Fogo AB. The role of angiotensin Ⅱ and plasminogen activator inhibitor-1 in progressive glomerulosclerosis. Am J Kidney Dis,2000,35(2) : 179.

二级参考文献7

共引文献38

同被引文献7

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部